Adjuvant concurrent chemoradiation using intensity-modulated radiotherapy and simultaneous integrated boost for resected high-risk adenocarcinoma of the distal esophagus and gastro-esophageal junction

Radiation Oncology

Edward Yu¹  George B Rodrigues²  A Rashid Dar¹  Richard I Inculet³  Richard A Malthaner³  Gregory Pierce¹  Abigail L Erickson¹  David A Palma¹  Brian P Yaremko¹ 

[1] Department of Radiation Oncology, Western University, London Regional Cancer Centre, 790 Commissioners Road East, N6A 4L6, London, ON, Canada;Department of Radiation Oncology and Department of Clinical Epidemiology and Biostatistics, Western University, London Regional Cancer Centre, 790 Commissioners Road East, N6A 4L6, London, ON, Canada;Department of Surgical Oncology, Western University, London Regional Cancer Centre, 790 Commissioners Road East, N6A 4L6, London, ON, Canada

关键词: SIB;    Simultaneous integrated boost;    Adjuvant;    IMRT;    GEJ;    Gastro-oesophageal junction;    Gastro-esophageal junction;   

Others  :  1154598
DOI  :  10.1186/1748-717X-8-33

 received in 2012-09-07, accepted in 2012-12-28,  发布年份 2013

【 摘 要 】

Purpose

Multimodality therapy leads to improved outcomes for adenocarcinoma of the distal esophagus and gastroesophageal junction (GEJ) over surgery alone. At our institution, adjuvant chemoradiation (chemoRT) using IMRT and SIB is standard of care for resected high-risk disease. In this study, we review our experience with a recent cohort of patients treated in this manner.

Methods and materials

We identified 18 patients with resected T3 and/or N1 adenocarcinoma of the distal esophagus and GEJ who received adjuvant chemoRT. A large elective volume (PTV1) and a smaller high-risk volume (PTV2) were irradiated simultaneously using IMRT and an SIB technique. All patients received concurrent chemotherapy. Relevant clinical outcomes are reported.

Results

The median dose to 95% of PTV1 was 3747cGy and to 95% of PTV2 was 4876cGy. All RT was given in a median of 28 daily fractions. Four patients did not complete chemotherapy. At a median follow up of 952 days from the start of RT, 7 of 18 patients were dead; of these, 3 had developed local recurrence only; 3 had developed both local and distant recurrence; 1 died of a late toxicity, without recurrence. OS was 88% at 1year, 76% at 2 years and 58% at 3 years. Freedom from local recurrence was 88% at 1 year, 82% at 2 years and 82% at 3 years. Freedom from distant recurrence was 72% at 1 year, 67% at 2 years and 56% at 3 years. Toxicity was acceptable.

Conclusions

Adjuvant concurrent chemoRT with IMRT and SIB is feasible for resected high-risk adenocarcinoma of the distal esophagus and GEJ. Our results describe how modern treatment techniques can be employed as part of a treatment paradigm that is neither commonly used nor commonly described in the literature.

【 授权许可】

   
2013 Yaremko et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Pera M: Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2000, 155:1-14. Epub 2000/02/29
• [2]Saito H, Sato T, Miyazaki M: Extramural lymphatic drainage from the thoracic esophagus based on minute cadaveric dissections: fundamentals for the sentinel node navigation surgery for the thoracic esophageal cancers. Surg Radiol Anat 2007, 29(7):531-542. Epub 2007/08/22
• [3]Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW: Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Annals of Surgery 2007, 246(1):1-8. Epub 2007/06/27
• [4]Heeren PA, Kelder W, Blondeel I, van Westreenen HL, Hollema H, Plukker JT: Prognostic value of nodal micrometastases in patients with cancer of the gastro-oesophageal junction. Eur J Surg Oncol: Eur J Soc Surg Oncol British Assoc Surg Oncol 2005, 31(3):270-276. Epub 2005/03/23
• [5]Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009, 27(30):5062-5067.
• [6]Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007, 8(3):226-234. Epub 2007/03/03
• [7]Graham AJ, Shrive FM, Ghali WA, Manns BJ, Grondin SC, Finley RJ: Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. Ann Thorac Surg 2007, 83(4):1257-1264. Epub 2007/03/27
• [8]Greer SE, Goodney PP, Sutton JE, Birkmeyer JD: Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 2005, 137(2):172-177. Epub 2005/01/28
• [9]Bedard EL, Inculet RI, Malthaner RA, Brecevic E, Vincent M, Dar R: The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer 2001, 91(12):2423-2430. Epub 2001/06/20
• [10]Yu E, Dar R, Rodrigues GB, Stitt L, Videtic GM, Truong P: Is extended volume external beam radiation therapy covering the anastomotic site beneficial in post-esophagectomy high risk patients? Radiother Oncol: Eur J Soc Therapeutic Radiol Oncol 2004, 73(2):141-148. Epub 2004/11/16
• [11]Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. Jama 1999, 281(17):1623-1627. Epub 1999/05/11
• [12]Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21(1):109-122.
• [13]Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB: Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl):S3-S9. Epub 2010/03/05
• [14]Services USDoHaH: Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. In Edited by Services DoHaH. 2010.
• [15]Yu E, Tai P, Younus J, Malthaner R, Truong P, Stitt L: Postoperative extended-volume external-beam radiation therapy in high-risk esophageal cancer patients: a prospective experience. Curr Oncol 2009, 16(4):48-54. Epub 2009/08/13
• [16]Yu E, Tai P, Malthaner R, Stitt L, Rodrigues G, Dar R: What are the factors that predict outcome at relapse after previous esophagectomy and adjuvant therapy in high-risk esophageal cancer? Curr Oncol 2010, 17(6):46-51. Epub 2010/12/15
• [17]Wu SD, Zhang P, Xie C, Zhang X, Jin Z: Phase II study of postoperative chemoradiotherapy for esophageal carcinoma. J Clin Oncol 2009, 27(suppl):abstr e15606.
• [18]Adelstein DJ, Rice TW, Rybicki LA, Saxton JP, Videtic GM, Murthy SC: Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol 2009, 4(10):1264-1269. Epub 2009/08/12
• [19]Rice TW, Adelstein DJ, Chidel MA, Rybicki LA, DeCamp MM, Murthy SC: Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg 2003, 126(5):1590-1596.
• [20]Lv J, Cao X-F, Zhu B, Ji L, Tao L, Wang D-D: Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. World J Gastroenterol 2010, 16(13):1649-1654.
• [21]Malthaner R: Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial (QUINTETT). ClinicalTrialsgov Identifier: NCT009075432009